The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Cancer-on-a-chip systems at the frontier of nanomedicine
Open accessAbstract
Nanomedicine provides a unique opportunity for promoting drug efficacy through enhanced delivery mechanisms. However, its translation into the clinics has been relatively slow compared with the large amount of research occurring in laboratory settings. Given the limitations of conventional cell culture models and preclinical animal models, we discuss the potential utility of recently developed cancer-on-a-chip platforms, which maximally replicate the pathophysiology of the human tumor microenvironments, as alternatives for effective evaluation of nanomedicine. We begin with a brief discussion of nanomedicine, then chart the history of organ-on-a-chip platform development and their recent evolution as tools for modeling different cancers for assessing nanomedicine efficacy, concluding with future perspectives for the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Today, tumor-on-chip systems are the most promising embodiment of in vitro platforms capable of faithfully recapitulation of relevant aspects of the biochemical complexity and dynamics of the tumor niche in a controlled environment (i.e., with much lower variability than is associated with in vivo systems [8,54,113]).”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Patient-on-chip platforms including engineered in vitro tissue models associated with patient derived cells (i.e. individual- and disease-specific hiPSCs) have the potential to revolutionize the drug discovery paradigm, and bring us closer towards the reality of personalized medicine [160,359,412].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [412]
In the citing paper
“Furthermore, microfluidic systems can link different organs-on-a-chip to potentially simulate the complexity of multiorgan drug metabolism and pharmacokinetics9,47,50,68–71.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [47]
In the citing paper
“Organ-on-a-chip devices possess good performance and improved recapitulation of the native microenvironment, and they allow high‐throughput tests with decreased cost, ethical advantages and enhanced reproducibility47,55–57.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,443
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,265
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Self-citationKim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,383
Self-citationOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Cited by
Sorted by citations
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P. P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,301
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Schneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal‐Öztürk, A., Saghazadeh, S., Sohail, M. F., Seo, J., Dokmeci, M. R., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 291
Self-citation
Metadata
- Authors
- Zhang, Y. S., Zhang, Y.-N., & Zhang, W.
- Affiliations
- Brigham and Women's Hospital (US)
- Fudan University (CN)
- Corresponding author
- Zhang, Yu Shrike
- Zhang, Weijia
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 22
- Issue
- 9
- Pages
- 1392-1399
- ISSN
- 1359-6446 (ISSN-L)
- PMC
- PMC5610924
- OpenAlex
- W2604347510
- Cited by
- 127
- References
- 73
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 16 · 2023: 11 · 2022: 13 · 2021: 19 · 2020: 14 · 2019: 19 · 2018: 17 · 2017: 8
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K99CA201603)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- organ-on-a-chip, nanomedicine, tumor microenvironment, drug delivery, preclinical models, microfluidic model
- MeSH terms
- Animals, Humans, Models, Biological, Neoplasms, Biomimetic Materials, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
